Hostname: page-component-8448b6f56d-xtgtn Total loading time: 0 Render date: 2024-04-18T20:12:14.246Z Has data issue: false hasContentIssue false
  • English
  • Français

The socio-economical burden of schizophrenia: A simulation of cost-offset of early intervention program in Italy

Published online by Cambridge University Press:  16 April 2020

Alessandro Serretti ,
Laura Mandelli ,
Emanuele Bajo ,
Nadia Cevenini ,
Pietro Papili ,
Elisa Mori ,
Marco Bigelli  and
Domenico Berardi
Alessandro Serretti*
Affiliation:
Institute of Psychiatry, University of Bologna, Italy
Laura Mandelli
Affiliation:
Institute of Psychiatry, University of Bologna, Italy
Emanuele Bajo
Affiliation:
Department of Management, University of Bologna, Italy
Nadia Cevenini
Affiliation:
Institute of Psychiatry, University of Bologna, Italy
Pietro Papili
Affiliation:
Institute of Psychiatry, University of Bologna, Italy
Elisa Mori
Affiliation:
Institute of Psychiatry, University of Bologna, Italy
Marco Bigelli
Affiliation:
Department of Management, University of Bologna, Italy
Domenico Berardi
Affiliation:
Institute of Psychiatry, University of Bologna, Italy
*
*Corresponding author. Tel.: +39 051 6584237; fax: +39 051 521030. E-mail address: alessandro.serretti@unibo.it (A. Serretti).
Get access

Abstract

Schizophrenia is associated with a high familiar, social and economic burden. During the recent years early and specific intervention for first psychotic episodes has been suggested to improve the long term outcome of the disease. Despite the promising results obtained so far, early intervention is still scarcely applied. One major problem arises from the translation of research findings into stakeholder policies. In fact very few analyses of cost reductions obtained with early intervention have been reported. In the present paper we present a simulation of direct cost reduction that can be obtained with early intervention programmes. We based our analysis on available data about schizophrenia care costs in Italy and the expected cost reduction with the use of early intervention. We observed that the increase in costs due to the more intensive early intervention is largely compensated by the reduction of inpatient admissions with a reduction of direct costs of 6.01%. Despite the apparently small economic gain, early intervention offers more clinical and social benefits as it seems to be effective also in decreasing relapse rates, in improving the patients' quality of life and disability associated with psychosis and in increasing employment rates. Those indirect costs however are difficult to estimate and were not included in our model.

In conclusion, our study supports the use of early intervention in schizophrenia, which could allow an outcome improvement with lower direct and indirect costs.

Keywords

SchizophreniaSocio-economic burdenPsychosocial interventionsPharmacoeconomicsCost-benefit
Type
Original article
Information
European Psychiatry , Volume 24 , Issue 1 , 2009 , pp. 11 - 16
Copyright
Copyright © Elsevier Masson SAS 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Addington, J., Leriger, E., Addington, D.Symptom outcome 1 year after admission to an early psychosis program. Can J Psychiatry 2003;48(3):204–207CrossRefGoogle Scholar
Amminger, G.P., Harris, M.G., Conus, P., Lambert, M., Elkins, K.S., Yuen, H.P.et al.Treated incidence of first-episode psychosis in the catchment area of EPPIC between 1997 and 2000. Acta Psychiatr Scand 2006;114(5):337–345CrossRefGoogle ScholarPubMed
Andrews, G., Sanderson, K., Corry, J., Issakidis, C., Lapsley, H.Cost-effectiveness of current and optimal treatment for schizophrenia. Br J Psychiatry 2003;183:427–435 discussion 436CrossRefGoogle Scholar
Arranz, M.J., Collier, D., Kerwin, R.W.Pharmacogenetics for the individualization of psychiatric treatment. Am J Pharmacogenomics 2001;1(1):3–10CrossRefGoogle ScholarPubMed
Arranz, M.J., Munro, J., Birkett, J., Bolonna, A., Mancama, D., Sodhi, M.et al.Pharmacogenetic prediction of clozapine response. Lancet 2000;355(9215):1615–1616CrossRefGoogle ScholarPubMed
Arranz, M.J., Munro, J., Osborne, S., Collier, D., Kerwin, R.W.Applications of pharmacogenetics in psychiatry: personalisation of treatment. Expert Opin Pharmacother 2001;2(4):537–542CrossRefGoogle ScholarPubMed
Carbone, S., Harrigan, S., McGorry, P.Duration of untreated psychosis and 12-month outcome in first-episode psychosis: the impact of treatment approach. Acta Psychiatr Scand 1999;100:96–104CrossRefGoogle ScholarPubMed
Davies, L.M., Drummond, M.F.Economics and schizophrenia: the real cost. Br J Psychiatry Suppl 1994;25:18–21CrossRefGoogle Scholar
Eccles, M., Mason, J.How to develop cost-conscious guidelines. Health Technol Assess 2001;5(16):1–69CrossRefGoogle ScholarPubMed
Haycox, A.Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. Pharmacoeconomics 2005;23(Suppl. 1):3–16CrossRefGoogle ScholarPubMed
Knapp, M.Costs of schizophrenia. Br J Psychiatry 1997;171:509–518CrossRefGoogle ScholarPubMed
Lauber, C., Keller, C., Eichenberger, A., Rossler, W.Family burden during exacerbation of schizophrenia: quantification and determinants of additional costs. Int J Soc Psychiatry 2005;51(3):259–264CrossRefGoogle ScholarPubMed
Lehman, A.F.Improving treatment for persons with schizophrenia. Psychiatr Q 1999;70(4):259–272CrossRefGoogle ScholarPubMed
Malhotra, A.K., Murphy, G.M. Jr.Kennedy, J.L.Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004;161(5):780–796CrossRefGoogle ScholarPubMed
Malla, A., Norman, R., Manchanda, R.Symptoms, cognition, treatment adherence and functional outcome in first-episode psychosis. Psychol Med 2002;32:1109–1119CrossRefGoogle ScholarPubMed
Malla, A., Norman, R., McLean, T.Impact of phase-specific treatment of first episode of psychosis on Wisconsin quality of life index (client version). Acta Psychiatr Scand 2001;103:355–361CrossRefGoogle Scholar
Marshall, M., Rathbone, J.Early intervention for psychosis. Cochrane Database Syst Rev 2006;4:CD004718CrossRefGoogle Scholar
McGlashan, T.H.A selective review of recent North American long-term followup studies of schizophrenia. Schizophr Bull 1988;14(4):515–542CrossRefGoogle ScholarPubMed
McGorry, P.D.The nature of schizophrenia: signposts to prevention. Aust N Z J Psychiatry 2000;34(Suppl):S14–S21CrossRefGoogle ScholarPubMed
McGorry, P.D., Edwards, J., Mihalopoulos, C., Harrigan, S.M., Jackson, H.J.EPPIC: an evolving system of early detection and optimal management. Schizophr Bull 1996;22(2):305–326CrossRefGoogle ScholarPubMed
Mihalopoulos, C., McGorry, P.D., Carter, R.C.Is phase-specific, community-oriented treatment of early psychosis an economically viable method of improving outcome?. Acta Psychiatr Scand 1999;100(1):47–55CrossRefGoogle ScholarPubMed
Mueser, K., McGurk, S.Schizophrenia. Lancet 2004;19:2063–2072CrossRefGoogle Scholar
Papili, P., Cevenini, N., Mori, E., Rossi, E., Mandelli, L., Michetti, R.et al.Early intervention in psychosis: pharmacological and psychosocial treatment. Minerva Psichiatr 2007;48(2):225–236Google Scholar
Percudani, M., Barbui, C., Tansella, M.Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective. Pharmacoeconomics 2004;22(11):701–718CrossRefGoogle Scholar
Polsky, D., Doshi, J.A., Bauer, M.S., Glick, H.A.Clinical trial-based cost-effectiveness analyses of antipsychotic use. Am J Psychiatry 2006;163(12):2047–2056CrossRefGoogle ScholarPubMed
Power, P., Elkins, K., Adlard, S.Analysis of the initial treatment phase in first-episode psychosis. Br J Psychiatry 1998;172(Suppl. 33):71–76CrossRefGoogle ScholarPubMed
Rossler, W., Salize, H.J., van Os, J., Riecher-Rossler, A.Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005;15(4):399–409CrossRefGoogle ScholarPubMed
Rouillon, F., Toumi, M., Dansette, G.Y., Benyaya, J., Auquier, P.Some aspects of the cost of schizophrenia in France. Pharmacoeconomics 1997;11(6):578–594CrossRefGoogle ScholarPubMed
Salize, H.J., Rossler, W.The cost of comprehensive care of people with schizophrenia living in the community. A cost evaluation from a German catchment area. Br J Psychiatry 1996;169(1):42–48CrossRefGoogle ScholarPubMed
Segman, R.H., Goltser, T., Heresco-Levy, U., Finkel, B., Shalem, R., Schlafman, M.et al.Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia. Pharmacogenomics J 2003;3(5):277–283CrossRefGoogle ScholarPubMed
Tarricone, R., Gerzeli, S., Montanelli, R., Frattura, L., Percudani, M., Racagni, G.Direct and indirect costs of schizophrenia in community psychiatric services in Italy. The GISIES study Interdisciplinary study group on the economic impact of schizophrenia Health Policy 2000;51(1):1–18CrossRefGoogle ScholarPubMed
Velligan, D.I., Kern, R.S., Gold, J.M.Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies. Schizophr Bull 2006;32(3):474–485CrossRefGoogle ScholarPubMed
Vos, T., Haby, M.M., Magnus, A., Mihalopoulos, C., Andrews, G., Carter, R.Assessing cost-effectiveness in mental health: helping policy-makers prioritize and plan health services. Aust N Z J Psychiatry 2005;39(8):701–712CrossRefGoogle ScholarPubMed
World Health Organization, Impact of disorders 2001 http://www.who.int/whr/2001/chapter2/en/index3.htmlGoogle Scholar
Zhang, M., Wang, M., Li, J., Phillips, M.R.Randomised-control trial of family intervention for 78 first-episode male schizophrenic patients. An 18-month study in Suzhou, Jiangsu. Br J Psychiatry Suppl 1994;24:96–102CrossRefGoogle Scholar
Zimbroff, D.L., Allen, M.H., Battaglia, J., Citrome, L., Fishkind, A., Francis, A.et al.Best clinical practice with ziprasidone IM: update after 2 years of experience. CNS Spectr 2005;10(9):1–15CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.